Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 69306-400; 0009-0038; 68071-5221; 71329-303; 68180-686; 57582-011; 0009-0022; 68788-4593; 22552-0029; 68382-918; 71329-305; 68180-687; 70121-1000; 82094-401; 70121-1001; 61919-149; 59746-002; 70518-1541; 68788-7833; 63629-2226; 45865-104; 68071-2370; 82094-405; 82094-403; 65162-980; 59762-0051; 70625-237; 63629-2218; 49999-153; 76420-041; 68071-2301; 59762-0049; 0009-0073; 76420-193; 68382-916; 59746-003; 71329-302; 82094-402; 71205-054; 63187-802; 59762-4440; 71205-453; 70771-1350; 59746-001; 71329-301; 70771-1351; 68180-689; 42806-400; 0781-5022; 72647-331; 60722-1003; 82094-404; 51552-0603; 68001-005; 51927-0201; 49452-4686; 68382-917; 70771-1348; 71329-304; 68382-919; 0603-4593; 65162-871; 59762-0050; 60760-373; 70786-0001; 65162-982; 70771-1349; 0009-0056; 50436-0001; 57582-101; 0009-0020; 0009-0176; 68071-4028; 59746-015; 64958-0084; 53002-3120; 82298-118; 63629-2433; 72189-264; 65162-984; 0904-6914; 69306-004; 63187-160; 50090-3811; 68084-149; 55289-649; 50090-0092; 45865-417; 50090-3094; 68180-688; 68180-685; 66267-961
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityTyrosine aminotransferaseP17735Not Available10485078; 10098101; 8719235; 1362219
HepatotoxicityGlucocorticoid receptorP04150T4001610485078; 10098101; 8719235; 1362219
Immune thrombocytopenic purpuraThrombopoietinP40225T99379Not Available
Immune thrombocytopenic purpuraP-selectinP16109T10965Not Available
Immune thrombocytopenic purpuraInterleukin-6P05231T32578Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gait disturbance17.02.05.016; 08.01.02.0020.000354%
Gastric haemorrhage24.07.02.007; 07.12.01.001--
Gastric ulcer07.04.03.0020.000142%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000566%Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000283%
Generalised tonic-clonic seizure17.12.01.0020.000142%Not Available
Glaucoma06.03.01.002--
Glucose tolerance impaired05.06.02.001; 14.06.02.001--
Glycosuria20.02.01.005--
Goitre14.11.01.008; 05.02.01.0010.000142%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.000055%Not Available
Haematuria20.02.01.006; 24.07.01.047--
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Hallucination19.10.02.0020.000354%
Headache17.14.01.0010.003680%
Heart rate increased13.14.04.0020.000283%Not Available
Heart rate irregular13.14.04.0030.000142%Not Available
Hepatic failure09.01.03.0020.000037%
Hepatitis09.01.07.0040.000425%Not Available
Hepatocellular injury09.01.07.0080.000142%Not Available
Hepatomegaly09.01.05.001--Not Available
Herpes zoster23.09.03.002; 11.05.02.0030.000212%
Hiccups22.02.04.002; 07.01.06.0090.000142%
Hirsutism23.02.04.001; 05.05.01.005--
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperglycaemia14.06.02.002; 05.06.02.0020.000212%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 15 Pages